Merck & Co., Inc. (MRK) to Release Earnings on Friday

Merck & Co., Inc. (NYSE:MRK) is scheduled to be announcing its earnings results before the market opens on Friday, February 2nd. Analysts expect the company to announce earnings of $0.94 per share for the quarter.

Shares of Merck & Co., Inc. (MRK) opened at $59.25 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. The company has a market cap of $161,600.00, a P/E ratio of 57.52, a P/E/G ratio of 3.07 and a beta of 0.76. Merck & Co., Inc. has a 12-month low of $53.63 and a 12-month high of $66.80.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 6th. Investors of record on Thursday, March 15th will be given a $0.48 dividend. The ex-dividend date is Wednesday, March 14th. This represents a $1.92 annualized dividend and a dividend yield of 3.24%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 186.41%.

Merck & Co., Inc. announced that its Board of Directors has approved a stock buyback plan on Tuesday, November 28th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Several equities research analysts recently commented on MRK shares. SunTrust Banks upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and upped their price target for the company from $54.00 to $72.00 in a research report on Tuesday, January 16th. BMO Capital Markets set a $70.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research report on Wednesday, October 11th. Jefferies Group restated a “sell” rating and issued a $55.00 price target on shares of Merck & Co., Inc. in a research report on Friday, October 20th. Leerink Swann reduced their price target on shares of Merck & Co., Inc. from $70.00 to $69.00 and set a “market perform” rating for the company in a research report on Monday, October 30th. Finally, ValuEngine upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $67.06.

In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 5,000 shares of the stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $58.00, for a total value of $290,000.00. Following the completion of the sale, the insider now owns 101,484 shares in the company, valued at approximately $5,886,072. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total transaction of $3,697,800.00. Following the completion of the sale, the insider now owns 101,484 shares of the company’s stock, valued at approximately $6,254,458.92. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,500 shares of company stock valued at $5,039,175. Insiders own 0.25% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Adalta Capital Management LLC raised its holdings in shares of Merck & Co., Inc. by 4.1% during the 2nd quarter. Adalta Capital Management LLC now owns 78,765 shares of the company’s stock valued at $5,085,000 after purchasing an additional 3,100 shares in the last quarter. High Falls Advisors Inc bought a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at $200,000. National Asset Management Inc. raised its holdings in shares of Merck & Co., Inc. by 1.3% during the 2nd quarter. National Asset Management Inc. now owns 50,243 shares of the company’s stock valued at $3,224,000 after purchasing an additional 622 shares in the last quarter. Piedmont Investment Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 0.3% during the 2nd quarter. Piedmont Investment Advisors LLC now owns 726,320 shares of the company’s stock valued at $46,550,000 after purchasing an additional 2,225 shares in the last quarter. Finally, Krilogy Financial LLC raised its holdings in shares of Merck & Co., Inc. by 0.4% during the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock valued at $201,000 after purchasing an additional 11 shares in the last quarter. Institutional investors own 73.58% of the company’s stock.

WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/01/merck-co-inc-mrk-to-release-earnings-on-friday.html.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Earnings History for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply